Katia Bassett

Katia has been leading CDx strategy, and collaborations with diagnostic partners, across both early-stage and late-stage portfolios at Genentech, for the past seven years. Currently, she oversees CDx development for Oncology Signaling, Rare Diseases, and OMNI (Ophthalmology, Metabolism, Neuroscience, Immunology, and Infectious Diseases). Previously, Katia had spent six years at Geron, leading translational research and CDx development in support of clinical programs for telomerase inhibitors. She earned her PhD in Biochemistry at the University of North Carolina at Chapel Hill.  She completed her post-doctoral training at the Lawrence Berkeley National Lab.